Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Feb 21, 2012 9:41pm
259 Views
Post# 19564482

MGMT UPDATE. Q4 2012 for Steady State?

MGMT UPDATE. Q4 2012 for Steady State?

Terry:

[S] Back on June 28, 2009 (Google: tonnes per face manshift), we discussed the potential scenarios we are now facing. i.e. How do we compare the BF UG to C/147 Zones. Meaning the oversized equipment that was replaced (equipment assumed in the NI 43-101) had a certain productivity assigned to it by an (Time and Motion Study, Industrial Engineering) IE department. Terms discussed would include tonnes per face manshift (UG versus C147 OP). There is also a "yardstick" called, "tonnes per haulage manshift".

 

Anyway, the cost per ounce poured will have another potential source of reductions as the overheads and tonnes broken per face M/S and tonnes hauled per M/S are introduced from C147.

 

BWDIK? What is the mandate for the "interim CE'? As s/he is critical to BRD PPS going foward.

As early as 1987, I had regular discussions with (U of T Geology prof) George Kent of Glimmer., I also had discussions with Exall/Denison, CMD & Glimmer personnel. Thus re-iterating I'm here based on the promise of the PROPERTY. BRD appears to be making all the right moves to unlock the "promise of the PROPERTY".

 

Cheers

Stanley

 

 

Bullboard Posts